Genentech pulls Raptiva from the U.S. market. Risk/benefit ratio got too dicey.
AstraZeneca gets a limited approval for Seroquel as add-on treatment for depression.
Layoffs + executive raises. Works for Sepracor, I guess.
PLUS: Goodbye, Willy Loman. From Pharmaceutical Executive.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply